Breaking News

CMP Pharma, Kiel Labs In Drug Development Pact

By Kristin Brooks | March 3, 2014

To develop two NDA products in liquid dosage form

CMP Pharma and Kiel Laboratories have signed an agreement to develop and commercialize two new drug products. Both drugs are approved by the FDA in solid dosage forms and CMP will file NDAs to gain approval for an alternate liquid dosage form.
 
CMP Pharma is a specialty pharmaceutical company located in Farmville, NC that develops and manufactures a portfolio of high-value topical and liquid pharmaceutical products. Kiel Laboratories, Inc., located in Flowery Branch, GA, provides drug development, regulatory and intellectual property services, and specializes in identification of and regulatory strategies around 505(b)(2) NDA submissions.     
 
Gerald Sakowski, chief executive officer of CMP Pharma, said, “These two products are excellent complements to our line of niche specialty pharmaceutical products. This is another chapter in our long history of developing stable, ready-to-use liquid dosage forms that make life easier on the consumer, the physician and the pharmacist.”

Related Contract Manufacturing:

Related Packaging:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.